“IBB has been less volatile during the past five years than any other biotech ETF and has been less volatile than all but one actively managed biotech mutual fund,” Goldsborough said. “A cap-weighted strategy has resulted in better risk-adjusted returns across one-, three-, five-, and 10-year time periods.”
iShares Nasdaq Biotechnology ETF
For more information on the biotech sector, visit our biotechnology category.
Max Chen contributed to this article.